LSPN 2016: UPC Agreement hasn’t reached a safe harbour yet

The Unified Patent Court Agreement has not quite reached a safe harbour yet, but it is close.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

Pharma

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.

Pharma

MSD’s Keytruda hit by eight-country ban across Europe

8 October 2026 Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.

More features

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Boston Scientific expands dispute with J&J unit over cardiac-access technology

Brazilian firm appoints patent strategist to lead department

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

Foley Hoag adds two partners in Denver expansion

LSPN 2016: UPC Agreement hasn’t reached a safe harbour yet

More on this story

Editor's picks

Editor's picks

More features